Related Experiment Video
Updated: Aug 15, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[DNA-chips in the diagnosis of hematological malignancies]
M Feuring-Buske1, E M Hartmann, G Ott
1Medizinische Klinik III, Klinikum Grosshadern der Ludwig-Maximilians-Universität München.
Insights
DNA-microarray gene expression profiling identified novel subgroups in hematological malignancies, including diffuse large B-cell lymphoma subtypes. These findings reveal new molecular classifications and predictive signatures for leukemia and lymphoma, aiding diagnosis.
Area of Science:
- Hematology
- Molecular Biology
- Genomics
Context:
- Hematological malignancies like lymphoma and leukemia are complex diseases.
- Traditional diagnostic criteria may not fully capture disease heterogeneity.
- Gene expression profiling offers a high-throughput approach to molecular characterization.
Purpose:
- To explore the utility of DNA-microarray gene expression profiling in classifying hematological malignancies.
- To identify novel molecular subgroups within lymphoma and leukemia.
- To discover gene expression signatures that predict clinical outcomes.
Summary:
- DNA-microarray analysis revealed distinct molecular subgroups within diffuse large B-cell lymphoma (DLBCL), including germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes, which exhibit different pathogenetic and clinical behaviors.
- In leukemia, gene expression profiling confirmed existing classifications and identified new molecular subgroups.
- Retrospective studies identified robust gene expression signatures capable of predicting the clinical course of lymphoma and leukemia at diagnosis.
Impact:
- Gene expression profiling enhances the understanding of hematological malignancy heterogeneity.
- Discovery of novel subgroups and predictive signatures can refine diagnosis and prognosis.
- The technology shows potential for integration into routine diagnostic workflows for improved patient management.
Abstract:
In hematological malignancies, gene expression profiling using DNA-microarrays led to the discovery of novel lymphoma and leukemia subgroups. The heterogeneous entity of diffuse large B-cell lymphoma could be subdivided into the germinal center B-cell-like and the activated B-cell-like subtype which differ in pathogenesis and clinical behavior. In leukemia, existing entities defined by morphological, cytogenetic, molecular and immunophenotypic criteria were confirmed on the global gene expression level; in addition, new important molecular subgroups could be identified. In retrospective clinical lymphoma and leukemia studies, robust gene expression signatures were discovered that predict the clinical course at the time of diagnosis. Given the huge potential of the DNA-microarray technology, application in the routine diagnostic setting appears possible.
